Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression
- PMID: 16941380
- DOI: 10.1086/507526
Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression
Abstract
For antiretroviral therapy, the 95% adherence "threshold" is based on nucloside-exposed patients who are receiving partially suppressive, unboosted protease inhibitor regimens. Using unannounced pill counts and electronic medication monitoring, viral suppression is common with a 54%-100% mean adherence level to nonnucleoside reverse-transcriptase-inhibitor regimens. Although perfect adherence is an important goal, viral suppression is possible with moderate adherence to potent regimens.
Comment in
-
Adherence to antiretroviral therapy: how much is enough?Clin Infect Dis. 2006 Oct 1;43(7):942-4. doi: 10.1086/507549. Epub 2006 Aug 23. Clin Infect Dis. 2006. PMID: 16941381 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical